施信如特聘研究員

中、英文摘要

腸病毒D68（EV-D68）除引起呼吸道感染，也可能造成神經疾病與肢體麻痺，目前無疫苗及專一性藥物。本院生醫所及生醫轉譯研究中心施信如團隊發現，病毒利用宿主微小RNA（miR-3156-3p）抑制鉀離子通道、增加鈣離子流入，促進囊泡介導的病毒釋放。

研究團隊以anti-miR抑制此微小RNA，降低病毒釋放；感染前給予小鼠，也能減輕麻痺症狀。此研究提出「以RNA對抗RNA病毒」的新策略，為抗病毒藥物開發提供方向。成果於2026年9月30日發表於《Molecular Therapy》，第一作者為林岳德博士，通訊作者為施信如特聘研究員，團隊涵蓋本院及長庚大學，研究經費由本院、國科會及長庚大學支持。

Enterovirus D68 (EV-D68) causes respiratory infections and may lead to neurological complications and paralysis. No vaccine and specific antiviral drug are available. A team led by Dr. Shin-Ru Shih at Academia Sinica discovered that EV-D68 exploits a host microRNA (miR-3156-3p) to suppress potassium channel activity and increase calcium influx, promoting vesicle-mediated viral release.

The researchers used an anti-miR to inhibit this microRNA, reducing viral release and alleviating paralysis when administered to mice before infection. These findings highlight a promising strategy for fighting RNA viruses using RNA-based approaches, offering new directions for antiviral drug development. Published in Molecular Therapy on September 30, 2026, the study lists Dr. Yueh-Te Lin as first author and Dr. Shin-Ru Shih as corresponding author. The research involved Academia Sinica and Chang Gung University, with funding from Academia Sinica, the National Science and Technology Council, and Chang Gung University.

論文全文連結

https://www.sciencedirect.com/science/article/pii/S1525001626008087?dgcid=author